Covidshield / Astrazeneca side effects
It's banned in many first world countries (Italy, Denmark etc. ) for younger population due to its rare side effect. Why isn't Indian govt following the suit? Why don't they share real data so that individual can make informed decisions?
Just fyi before people bash me. Covidshield is no brainer for anyone older than 30. For young peeps, no so much (given low virus prevelance). Given majority of Indian population is < 30, govt should consider rare side effects. Solution might be to promote Pfizer, sputnik vaccines for this age group.
Pfizer requires -70 degree storage. No such infrastructure available in hospitals or vaccination centers. Also pfizer demands legal protection in case of side effects
Unsurprising on Pfizer. They skipped phase 2 and phase 3 testing. Sometime Google about how many vaccines have been killed in phase 2 and phase 3 testing and you’ll realize joke is on us for letting them inject a science experiment for a virus with well over a 99% survival rate (99.99% for healthy young people)
The physiology of european and westerns populations is different from Indian
Oxford AstraZeneca is manufactured in much larger quantity in India (at Serum), storage is easier and the alternatives (Pfizer, moderna, J&J) were either approved very late or aren't available readily in India. Also, add UK to your list of countries where people under 40 aren't given OxfAZ. https://www.bbc.co.uk/news/health-57021738
What abut covaxin? Heard its much safer for younger and older population and better efficacy rate of 80%? Sputnik is best i heard with 90 % efficacy and mild or no side affects. ( not sure if it will be the same for India produced sputnik)
They're all trash. Avoid like the plague.
Not true. There have been many cases of blood clots after OxfAZ in UK+EU, so UK government made an early decision to not give OxfAZ to people under 40. Almost all people under 40 are getting Pfizer or Moderna. https://www.bbc.co.uk/news/health-57021738
Because the benefits outweigh the risks. Atleast for India - where chances of spreading, mutating are much higher because of the population density.
Agreed that benefits far outweighs risks for older population. Its still borderline for younger population though.
But right now India has to weigh the risks to the entire population. Younger age groups are still carriers and spreaders and since the general population at large is at increased risk; at a macro level the benefits outweigh the risks. At an individual level, they probably don’t.